BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. a leader in lung cancer diagnostics, is extending its blood-based testing portfolio with the release of the Nodify CDT TM test, designed to help ...
Biodesix, Inc. BDSX recently announced a new post-market clinical validation study, published in CHEST Pulmonary Journal. The study reaffirms the previously established performance of the BDSX’s ...
BOULDER, Colo.--(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, ...
The payment amount for the Nodify CDT test as established by the Medicare Administrative Contractor is $649. "Receiving ADLT status is a major milestone for Biodesix and confirms the clinical value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results